Noxopharm Ltd has released a press release.
LuPIN Prostate Cancer Trial Fully Recruited
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Half Year Accounts and Chairman Letter
- FDA grants IND approval to Veyonda
- Noxopharm Alliance With GenesisCare
- LuPIN Trial Interim Results Indicate Striking Survival Benefit
- $8.1M Financing & Re-Set of Capital Structure
Later from Noxopharm
- Veyonda Awarded First Allowed Patent Application
- Noxopharm Investigating Potential COVID-19 Treatment
- Approval to be sought for COVID-19 Clinical Study in U.S.
- Pipeline Expands With Potential New Brain Cancer Treatment
- Abscopal Responses Achieved in Prostate Cancer
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm